Important Safety Information   |   Prescribing Information

HemophiliaVillage
1. Bolton-Maggs PHB, Pasi KJ. Haemophilias A and B. Lancet. 2003;361:1801-1809.
2. National Center on Birth Defects and Developmental Disabilities. Hereditary Blood Disorders: Hereditary Bleeding Disorders. Atlanta, GA: Centers for Disease Control and Prevention. National Institutes of Health, US Department of Health and Human Services. Available at: http://www.cdc.gov/ncbddd/hbd/hemophilia.htm. Accessed July 3, 2008.
3. National Heart, Lung, and Blood Institute. What Is Hemophilia? Bethesda, Md: National Institutes of Health, US Department of Health and Human Services. Available at: http://www.nhlbi.nih.gov/health/dci/Diseases/hemophilia/hemophilia_what.html. Accessed July 3, 2008.
4. Dunn AL, Abshire TC. Recent advances in the management of the child who has hemophilia. Hematol Oncol Clin N Am. 2004;18:1249-1276.
5. National Heart, Lung, and Blood Institute. Other Names for Hemophilia. Bethesda, Md: National Institutes of Health, US Department of Health and Human Services. Available at: http://www.nhlbi.nih.gov/health/dci/Diseases/hemophilia/hemophilia_onames.html. Accessed July 3, 2008.
6. National Heart, Lung, and Blood Institute. What Are the Signs and Symptoms of Hemophilia? Bethesda, Md: National Institutes of Health, US Department of Health and Human Services. Available at: http://www.nhlbi.nih.gov/health/dci/Diseases/hemophilia/hemophilia_signs.html. Accessed July 3, 2008.
7. National Heart, Lung, and Blood Institute. How Is Hemophilia Diagnosed? Bethesda, Md: National Institutes of Health, US Department of Health and Human Services. Available at: http://www.nhlbi.nih.gov/health/dci/Diseases/hemophilia/hemophilia_diagnosis.html. Accessed July 3, 2008.
8. National Heart, Lung, and Blood Institute. How Is Hemophilia Treated? Bethesda, Md: National Institutes of Health, US Department of Health and Human Services. Available at: http://www.nhlbi.nih.gov/health/dci/Diseases/hemophilia/hemophilia_treatments.html. Accessed July 3, 2008.
9. Statement by Kathryn C. Zoon, PhD, Director, Center for Biologics Evaluation and Research, Food and Drug Administration, Department of Health and Human Services, Before the Subcommittee on Human Resources and Intergovernmental Relations, Committee on Government Reform and Oversight. U.S. House of Representatives, July 31, 1997. Available at: http://www.fda.gov/ola/plasma.htm. Accessed July 3, 2008.
10. Food and Drug Administration. New Recombinant Antihemophilic Factor Licensed. Rockville, Md: National Press Office; July 23, 2003. Talk Paper T03-55. Available at: http://www.fda.gov/bbs/topics/ANSWERS/ANS00786.html. Accessed July 3, 2008.
11. Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. N Engl J Med. 1990;323:1800-1805.
12. Roth DA, Kessler CM, Pasi KJ, et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood. 2001;98:3600-3606.
13. National Heart, Lung, and Blood Institute. Living With Hemophilia. Bethesda, Md: National Institutes of Health, US Department of Health and Human Services. Available at: http://www.nhlbi.nih.gov/health/dci/Diseases/hemophilia/hemophilia_living.html. Accessed July 3, 2008.
14. World Federation of Hemophilia. Frequently asked questions about hemophilia. Available at: http://www.wfh.org/2/1/1_1_1_FAQ.htm. Accessed July 3, 2008.
15. Manco-Johnson MJ, Blanchette VS. North American prophylaxis studies for persons with severe haemophilia: background, rationale, and design. Haemophilia. 2003;9(suppl 1):44-49.
16. Szucs TD, Öffner A, Schramm W. Socioeconomic impact of haemophilia care: results of a pilot study. Haemophilia. 1996;2:211-217.
17. Berntorp E, Lethagen S. The role of home infusion therapy in hæmophilia: a disease management perspective. Dis Manage Health Outcomes. 2000;7:77-81.
18. Playing It Safe. Bleeding Disorders, Sports and Exercise. National Hemophilia Foundation 2005.
19. Arun B, Kessler CM. Clinical manifestations and therapy of the hemophilias. In: Colman RW, Hirsh J, Marder VJ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:815-824.
20. Fiebig EW, Busch MP. Emerging infections in transfusion medicine. Clin Lab Med. 2004:24;797-823.
21. Kessler CM. New perspectives in hemophilia treatment. Hematology. 2005:429-435.
22. XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin Free, Wyeth Pharmaceuticals Inc.
23. Data on file, Wyeth Pharmaceuticals Inc.
24. ReFacto® Antihemophilic Factor (Recombinant) Prescribing Information, Wyeth Pharmaceuticals Inc.
25. BeneFIX® Coagulation Factor IX (Recombinant) Prescribing Information, Wyeth Pharmaceuticals Inc.
26. National Hemophilia Foundation Medical and Scientific Advisory Council (MASAC). MASAC Recommendations Concerning the Treatment of Hemophilia and Other Bleeding Disorders. New York, NY:NHF; October 2006. MASAC Document #177.